While sirolimus has demonstrated having activity for EHE, it is only one drug and will not work in all cases. The EHE Foundation (US) are funding other significant research projects that each aim to screen other existing FDA-approved drugs to identify those that may have activity for EHE.
One such project is led by Dr John Lamar, based at the Albany Medical College in New York. Dr Lamar’s group are investigating the use of pre-clinical EHE models to identify druggable pathways to treat EHE to reveal pathways that can be targeted with existing FDA-approved drugs to either eliminate EHE or prevent its growth.